Subcutaneous injections do not require a port like an IV, eliminating the risk for port-related complications such as infections.

The Ocrevus subcutaneous injection was shown to be non-inferior to the IV, as measured by pharmacokinetics (levels in the blood) over 12 weeks. The subcutaneous injection was also comparable in ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

The Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for all previously approved indications of the intravenous ...

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.Nivolumab and ...

Session ID: 2025-08-18:1dc0394f2aa8bdcca129a32b Player Element ID: vjs_video_3 ...